Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Atea Pharmaceuticals, Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are distributed among 3 distinct examiners and 3 distinct art units.
KOSAR, ANDREW D is the busiest examiner with 1 pending office action. Because each of the 3 actions is in a different art unit with a different examiner, there is no shared personnel or unit-level oversight across the 3 matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSAR, ANDREW D | 1 | 41.9% | +31.9% |
| MCINTOSH III, TRAVISS C | 1 | 73.3% | +14.1% |
| CRAIGO, BAHAR ALAWI | 1 | 47.3% | +27.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18957362 | DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION | KOSAR, ANDREW D | — |
| 18828972 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | MCINTOSH III, TRAVISS C | — |
| 18592037 | 2'-CHLORO-2'-FLUORO-N2-AMINO-N6-METHYLAMINO PURINE NUCLEOTIDES FOR FLAVIVIRUS TREATMENT | CRAIGO, BAHAR ALAWI | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1693 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18957362 | DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION | KOSAR, ANDREW D | 1625 | §103 | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18828972 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | MCINTOSH III, TRAVISS C | 1693 | DP | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18592037 | 2'-CHLORO-2'-FLUORO-N2-AMINO-N6-METHYLAMINO PURINE NUCLEOTIDES FOR FLAVIVIRUS TREATMENT | CRAIGO, BAHAR ALAWI | 1699 | §103DP | Non-Final OA | — | Pending | Feb 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAtea Pharmaceuticals, Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Andrew D Kosar has the most, with 1 of Atea Pharmaceuticals, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
